Mindpeak Resources

Latest News
Posters

Latest News

Press Release

Mindpeak at Handelsblatt Pharma Congress 2026

At this year’s Handelsblatt Live Pharma Congress 2026, our CEO Felix Faber addressed one of the industry’s most pressing challenges: the high failure rate of clinical trials.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
In the News

Mindpeak sets standards with PD-L1 Cell Atlas

10 Oct 2023
In the News

Diagnostic throughput increased by up to 10x and more patients identified.

03 Aug 2023
Press Release

Mindpeak and Proscia team up!

20 Jun 2023
Events

Meet our experts at ECDP!

14 Jun 2022
Press Release

Mindpeak announces scanner agnostic CE-marked PD-L1 AI solution to support Lung Cancer Diagnosis

09 Jun 2022
Press Release

Mindpeak announces first CE-marked fully automated software to support breast cancer tissue diagnosis

24 May 2022
Events

Join our Keynote on 11EPUCG2022!

05 May 2022
Events

Meet our Experts at USCAP!

02 Mar 2022
Events

Meet our experts at 8th DPAC

05 Nov 2021

Blog and Case Studies

No items found.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

Research and Science Publications

H&E

SUPERB - AI SUPported Evaluation of Immunotherapy Response in Early Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes. Immunotherapy offers new treatment options, but only a subset of patients responds effectively. The SUPERB project addresses this challenge by developing an AI-supported predictive biomarker.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
IHC

Enhancing HER2 IHC Interpretation in Breast Cancer with AI Assistance: Focus on Ultralow Expression in a Multicenter Study across Asia

Emerging therapies for HER2-low and -ultralow breast cancer emphasize the need for precise and consistent HER2 IHC scoring. However, interpretation remains challenging due to staining variability and subjective thresholds. AI tools may improve diagnostic accuracy and reproducibility, yet real-world data across multiple centers - especially for HER2-ultralow expression - to date is sparse.

07 Dec 2025
IHC

Quantitative and qualitative evaluation of an AI-assistance software for PD-L1 TPS assessment in non-small cell lung cancer (NSCLC)

In summary, the AI software investigated was found to increase both accuracy and interobserver agreement of pathologists in PD-L1 NSCLC TPS scoring and was reported to be helpful and user-friendly for application in a routine diagnostic workflow.

14 Nov 2025
IHC

Augmenting HER2 IHC Assessment, Including HER2 Ultralow Scoring, in Breast Cancer with AI Support: A Multinational Observational Study

The emergence of novel therapies targeting low and ultralow HER2 expression in breast cancer stresses the need for accurate, reproducible HER2 immunohistochemistry (IHC) assessment.

21 Oct 2025
IHC

Al-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners

Using challenging validation data from three institutions and four scanners, ROI scoring with the support of our Al. PD-L1 quantifier showed high agreement with pathologists, while significantly reducing assessment time.

H&E

Large-Scale Validation of a Robust Artificial Intelligence Algorithm for Detection of Invasive Breast Cancer on H&E Images

The evaluation against pathologist assessments on - to our knowledge - the most diverse datasets used so far demonstrated that the investigated Al system achieves high accuracy in the detection of invasive breast cancer.

17 May 2025

Mindpeak's HER2 low comes out on top in comparative study by Cypath

In a first of its kind comparative study, Mindpeak's CE-marked HER2 AI for breast cancer diagnosis was compared to three other commercial AIs (e.g. Visiopharm).

17 Apr 2023
IHC

Poster HER2-low presented at ASCO2023

Our #ASCO2023 poster on HER2-low was selected for oral presentation by session chair Prof. David Rimm (Yale University School of Medicine). In his discussion he highlighted AI as an essential means to score HER2 in the future.

04 Jun 2023
IHC

Mindpeak’s PD-L1 CPS AI to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance

Our study, presented at ASCO 2024, investigated the use of AI-based software to assess PD-L1 expression in gastric cancer. The AI demonstrated a higher agreement with pathologists than pathologists with each other, while classifying more patients as eligible for immunotherapy. 

18 Oct 2024
H&E

Multi-Modal AI Outperforms Image-Only Approaches for Mutation Prediction in Colorectal Cancer

In our latest study in collaboration with University of Pennsylvania Perelman School of Medicine we demonstrate how our multi-modal predictive AI model outperforms image-only approaches for mutation prediction in colorectal cancer.

18 Nov 2024

FAQ

Essential definitions for AI, pathology, and regulatory frameworks

How does Mindpeak address bias in AI systems?

Mindpeak prioritizes diverse data curation, cross-site validation and continuous monitoring to support responsible and generalisable AI deployment across clinical environments.

‍

How is Mindpeak deployed across laboratories?

Mindpeak integrates with established digital pathology infrastructures and supports scalable deployment across laboratory networks and pharmaceutical partnerships.

What staining modalities are supported?

peakFrontier operates across multiplex immunofluorescence, immunohistochemistry and H&E, enabling consistent analysis across discovery, translational research and clinical development workflows.

Is Mindpeak software approved for clinical use?

Yes. Mindpeak offers CE-IVD certified diagnostic products and operates under an ISO 13485 certified quality management system.

More questions?

Reach out to our team directly

Contact

Ready to modernize your lab?

See how our diagnostic suites fit your workflow and accelerate your results.

Book a Demo